Incorporation and metabolic conversion of saturated and unsaturated fatty acids in SK-Hep1 human hepatoma cells in culture

C. A. Marra,M. J. Alaniz

DOI: https://doi.org/10.1007/BF00230749

IF: 3.842

1992-11-18

Molecular and Cellular Biochemistry

Abstract:

What problem does this paper attempt to address?

Targeting metabolism to enhance immunotherapy within tumor microenvironment

Xiao-hui Liang,Xin-yi Chen,Yue Yan,Ao-yu Cheng,Jia-yi Lin,Yi-xin Jiang,Hong-zhuan Chen,Jin-mei Jin,Xin Luan

DOI: https://doi.org/10.1038/s41401-024-01304-w

IF: 7.169

2024-05-30

Acta Pharmacologica Sinica

Abstract:Cancer metabolic reprogramming has been considered an emerging hallmark in tumorigenesis and the antitumor immune response. Like cancer cells, immune cells within the tumor microenvironment or premetastatic niche also undergo extensive metabolic reprogramming, which profoundly impacts anti-tumor immune responses. Numerous evidence has illuminated that immunosuppressive TME and the metabolites released by tumor cells, including lactic acid, Prostaglandin E2 (PGE2), fatty acids (FAs), cholesterol, D-2-Hydroxyglutaric acid (2-HG), adenosine (ADO), and kynurenine (KYN) can contribute to CD8 + T cell dysfunction. Dynamic alterations of these metabolites between tumor cells and immune cells can similarly initiate metabolic competition in the TME, leading to nutrient deprivation and subsequent microenvironmental acidosis, which impedes immune response. This review summarizes the new landscape beyond the classical metabolic pathways in tumor cells, highlighting the pivotal role of metabolic disturbance in the immunosuppressive microenvironment, especially how nutrient deprivation in TME leads to metabolic reprogramming of CD8 + T cells. Likewise, it emphasizes the current therapeutic targets or strategies related to tumor metabolism and immune response, providing therapeutic benefits for tumor immunotherapy and drug development in the future.

pharmacology & pharmacy,chemistry, multidisciplinary
Metabolic Reprogramming of Immune Cells in the Tumor Microenvironment

Jing Wang,Yuanli He,Feiming Hu,Chenchen Hu,Yuanjie Sun,Kun Yang,Shuya Yang

DOI: https://doi.org/10.3390/ijms252212223

IF: 5.6

2024-11-18

International Journal of Molecular Sciences

Abstract:Metabolic reprogramming of immune cells within the tumor microenvironment (TME) plays a pivotal role in shaping tumor progression and responses to therapy. The intricate interplay between tumor cells and immune cells within this ecosystem influences their metabolic landscapes, thereby modulating the immune evasion tactics employed by tumors and the efficacy of immunotherapeutic interventions. This review delves into the metabolic reprogramming that occurs in tumor cells and a spectrum of immune cells, including T cells, macrophages, dendritic cells, and myeloid-derived suppressor cells (MDSCs), within the TME. The metabolic shifts in these cell types span alterations in glucose, lipid, and amino acid metabolism. Such metabolic reconfigurations can profoundly influence immune cell function and the mechanisms by which tumors evade immune surveillance. Gaining a comprehensive understanding of the metabolic reprogramming of immune cells in the TME is essential for devising novel cancer therapeutic strategies. By targeting the metabolic states of immune cells, it is possible to augment their anti-tumor activities, presenting new opportunities for immunotherapeutic approaches. These strategies hold promise for enhancing treatment outcomes and circumventing the emergence of drug resistance.

biochemistry & molecular biology,chemistry, multidisciplinary
Metabolic reprogramming in tumor immune microenvironment: Impact on immune cell function and therapeutic implications

Yuqiang Liu,Yu Zhao,Huisheng Song,Yunting Li,Zihao Liu,Zhiming Ye,Jianzhu Zhao,Yuzheng Wu,Jun Tang,Maojin Yao

DOI: https://doi.org/10.1016/j.canlet.2024.217076

2024-08-10

Abstract:Understanding of the metabolic reprogramming has revolutionized our insights into tumor progression and potential treatment. This review concentrates on the aberrant metabolic pathways in cancer cells within the tumor microenvironment (TME). Cancer cells differ from normal cells in their metabolic processing of glucose, amino acids, and lipids in order to adapt to heightened biosynthetic and energy needs. These metabolic shifts, which crucially alter lactic acid, amino acid and lipid metabolism, affect not only tumor cell proliferation but also TME dynamics. This review also explores the reprogramming of various immune cells in the TME. From a therapeutic standpoint, targeting these metabolic alterations represents a novel cancer treatment strategy. This review also discusses approaches targeting the regulation of metabolism of different nutrients in tumor cells and influencing the tumor microenvironment to enhance the immune response. In summary, this review summarizes metabolic reprogramming in cancer and its potential as a target for innovative therapeutic strategies, offering fresh perspectives on cancer treatment.
Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy

Xin Lian,Kailin Yang,Renliang Li,Maomao Li,Jing Zuo,Bohao Zheng,Wei Wang,Ping Wang,Shengtao Zhou

DOI: https://doi.org/10.1186/s12943-021-01486-5

IF: 37.3

2022-01-21

Molecular Cancer

Abstract:Abstract Cellular metabolism constitutes a fundamental process in biology. During tumor initiation and progression, each cellular component in the cancerous niche undergoes dramatic metabolic reprogramming, adapting to a challenging microenvironment of hypoxia, nutrient deprivation, and other stresses. While the metabolic hallmarks of cancer have been extensively studied, the metabolic states of the immune cells are less well elucidated. Here we review the metabolic disturbance and fitness of the immune system in the tumor microenvironment (TME), focusing on the impact of oncometabolites to the function of immune cells and the clinical significance of targeting metabolism in anti-tumor immunotherapy. Metabolic alterations in the immune system of TME offer novel therapeutic insight into cancer treatment.

oncology,biochemistry & molecular biology
Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy

Jackie E. Bader,Kelsey Voss,Jeffrey C. Rathmell

DOI: https://doi.org/10.1016/j.molcel.2020.05.034

IF: 16

2020-06-01

Molecular Cell

Abstract:The growing field of immune metabolism has revealed promising indications for metabolic targets to modulate anti-cancer immunity. Combination therapies involving metabolic inhibitors with immune checkpoint blockade (ICB), chemotherapy, radiation, and/or diet now offer new approaches for cancer therapy. However, it remains uncertain how to best utilize these strategies in the context of the complex tumor microenvironment (TME). Oncogene-driven changes in tumor cell metabolism can impact the TME to limit immune responses and present barriers to cancer therapy. These changes also reveal opportunities to reshape the TME by targeting metabolic pathways to favor immunity. Here we explore current strategies that shift immune cell metabolism to pro-inflammatory states in the TME and highlight a need to better replicate physiologic conditions to select targets, clarify mechanisms, and optimize metabolic inhibitors. Unifying our understanding of these pathways and interactions within the heterogenous TME will be instrumental to advance this promising field and enhance immunotherapy.

cell biology,biochemistry & molecular biology
Targeting lipid metabolism reprogramming of immunocytes in response to the tumor microenvironment stressor: A potential approach for tumor therapy

Ming Zhang,Tingju Wei,Xiaodan Zhang,Danfeng Guo

DOI: https://doi.org/10.3389/fimmu.2022.937406

IF: 7.3

2022-09-05

Frontiers in Immunology

Abstract:The tumor microenvironment (TME) has become a major research focus in recent years. The TME differs from the normal extracellular environment in parameters such as nutrient supply, pH value, oxygen content, and metabolite abundance. Such changes may promote the initiation, growth, invasion, and metastasis of tumor cells, in addition to causing the malfunction of tumor-infiltrating immunocytes. As the neoplasm develops and nutrients become scarce, tumor cells transform their metabolic patterns by reprogramming glucose, lipid, and amino acid metabolism in response to various environmental stressors. Research on carcinoma metabolism reprogramming suggests that like tumor cells, immunocytes also switch their metabolic pathways, named "immunometabolism", a phenomenon that has drawn increasing attention in the academic community. In this review, we focus on the recent progress in the study of lipid metabolism reprogramming in immunocytes within the TME and highlight the potential target molecules, pathways, and genes implicated. In addition, we discuss hypoxia, one of the vital altered components of the TME that partially contribute to the initiation of abnormal lipid metabolism in immune cells. Finally, we present the current immunotherapies that orchestrate a potent antitumor immune response by mediating the lipid metabolism of immunocytes, highlight the lipid metabolism reprogramming capacity of various immunocytes in the TME, and propose promising new strategies for use in cancer therapy.

immunology
Metabolic reprograming of MDSCs within tumor microenvironment and targeting for cancer immunotherapy

Qing Li,Ming Xiang

DOI: https://doi.org/10.1038/s41401-021-00776-4

IF: 7.169

2021-09-24

Acta Pharmacologica Sinica

Abstract:A number of emerging studies in field of immune metabolism have indicated that cellular metabolic reprograming serves as a major administrator in maintaining the viability and functions of both tumor cells and immune cells. As one of the most important immunosuppressive cells in tumor stroma, myeloid-derived suppressor cells (MDSCs) dynamically orchestrate their metabolic pathways in response to the complicated tumor microenvironment (TME), a process that consequently limits the therapeutic effectiveness of anti-cancer treatment modalities. In this context, the metabolic vulnerabilities of MDSCs could be exploited as a novel immune metabolic checkpoint upon which to intervene for promoting the efficacy of immunotherapy. Here, we have discussed about recent studies highlighting the important roles of the metabolic reprograming and the core molecular pathways involved in tumor-infiltrating MDSCs. In addition, we have also summarized the state-of-the-art strategies that are currently being employed to target MDSC metabolism and improve the efficacy of antineoplastic immunotherapy.

pharmacology & pharmacy,chemistry, multidisciplinary
Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer

Yi Wang,Yuya Wang,Yifei Ren,Qi Zhang,Ping Yi,Chunming Cheng

DOI: https://doi.org/10.1016/j.semcancer.2022.02.010

IF: 17.012

2022-02-01

Seminars in Cancer Biology

Abstract:Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) or programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1)-based immune checkpoint inhibitors (ICIs) have led to significant improvements in the overall survival of patients with certain cancers and are expected to benefit patients by achieving complete, long-lasting remissions and cure. However, some patients who receive ICIs either fail treatment or eventually develop immunotherapy resistance. The existence of such patients necessitates a deeper understanding of cancer progression, specifically nutrient regulation in the tumor microenvironment (TME), which includes both metabolic cross-talk between metabolites and tumor cells, and intracellular metabolism in immune and cancer cells. Here we review the features and behaviors of the TME and discuss the recently identified major immune checkpoints. We comprehensively and systematically summarize the metabolic modulation of tumor immunity and immune checkpoints in the TME, including glycolysis, amino acid metabolism, lipid metabolism, and other metabolic pathways, and further discuss the potential metabolism-based therapeutic strategies tested in preclinical and clinical settings. These findings will help to determine the existence of a link or crosstalk between tumor metabolism and immunotherapy, which will provide an important insight into cancer treatment and cancer research.

oncology
Metabolic interventions: A new insight into the cancer immunotherapy

Tao Yu,Tianhan Dong,Haniyeh Eyvani,Yuanzhang Fang,Xiyu Wang,Xinna Zhang,Xiongbin Lu

DOI: https://doi.org/10.1016/j.abb.2020.108659

IF: 4.114

2021-01-01

Archives of Biochemistry and Biophysics

Abstract:Metabolic reprogramming confers cancer cells plasticity and viability under harsh conditions. Such active alterations lead to cell metabolic dependency, which can be exploited as an attractive target in development of effective antitumor therapies. Similar to cancer cells, activated T cells also execute global metabolic reprogramming for their proliferation and effector functions when recruited to the tumor microenvironment (TME). However, the high metabolic activity of rapidly proliferating cancer cells can compete for nutrients with immune cells in the TME, and consequently, suppressing their anti-tumor functions. Thus, therapeutic strategies could aim to restore T cell metabolism and anti-tumor responses in the TME by targeting the metabolic dependence of cancer cells. In this review, we highlight current research progress on metabolic reprogramming and the interplay between cancer cells and immune cells. We also discuss potential therapeutic intervention strategies for targeting metabolic pathways to improve cancer immunotherapy efficacy.
The cancer metabolic reprogramming and immune response

Longzheng Xia,Linda Oyang,Jinguan Lin,Shiming Tan,Yaqian Han,Nayiyuan Wu,Pin Yi,Lu Tang,Qing Pan,Shan Rao,Jiaxin Liang,Yanyan Tang,Min Su,Xia Luo,Yiqing Yang,Yingrui Shi,Hui Wang,Yujuan Zhou,Qianjin Liao

DOI: https://doi.org/10.1186/s12943-021-01316-8

IF: 37.3

2021-02-05

Molecular Cancer

Abstract:Abstract The overlapping metabolic reprogramming of cancer and immune cells is a putative determinant of the antitumor immune response in cancer. Increased evidence suggests that cancer metabolism not only plays a crucial role in cancer signaling for sustaining tumorigenesis and survival, but also has wider implications in the regulation of antitumor immune response through both the release of metabolites and affecting the expression of immune molecules, such as lactate, PGE 2 , arginine, etc. Actually, this energetic interplay between tumor and immune cells leads to metabolic competition in the tumor ecosystem, limiting nutrient availability and leading to microenvironmental acidosis, which hinders immune cell function. More interestingly, metabolic reprogramming is also indispensable in the process of maintaining self and body homeostasis by various types of immune cells. At present, more and more studies pointed out that immune cell would undergo metabolic reprogramming during the process of proliferation, differentiation, and execution of effector functions, which is essential to the immune response. Herein, we discuss how metabolic reprogramming of cancer cells and immune cells regulate antitumor immune response and the possible approaches to targeting metabolic pathways in the context of anticancer immunotherapy. We also describe hypothetical combination treatments between immunotherapy and metabolic intervening that could be used to better unleash the potential of anticancer therapies.

oncology,biochemistry & molecular biology
Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy

Suling Xu,Qingqing Wang,Wenxue Ma

DOI: https://doi.org/10.1016/j.cytogfr.2024.02.003

IF: 17.66

2024-01-01

Cytokine & Growth Factor Reviews

Abstract:Navigating the intricate landscape of the tumor microenvironment (TME) unveils a pivotal arena for cancer therapeutics, where cytokines and soluble mediators emerge as double-edged swords in the fight against cancer. This review ventures beyond traditional perspectives, illuminating the nuanced interplay of these elements as both allies and adversaries in cancer dynamics. It critically evaluates the evolving paradigms of TME reprogramming, spotlighting innovative strategies that target the sophisticated network of cytokines and mediators. Special focus is placed on unveiling the therapeutic potential of novel cytokines and mediators, particularly their synergistic interactions with extracellular vesicles, which represent underexplored conduits for therapeutic targeting. Addressing a significant gap in current research, we explore the untapped potential of these biochemical players in orchestrating immune responses, tumor proliferation, and metastasis. The review advocates for a paradigm shift towards exploiting these dynamic interactions within the TME, aiming to transcend conventional treatments and pave the way for a new era of precision oncology. Through a critical synthesis of recent advancements, we highlight the imperative for innovative approaches that harness the full spectrum of cytokine and mediator activities, setting the stage for breakthrough therapies that offer heightened specificity, reduced toxicity, and improved patient outcomes.
Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints

Yaolin Xu,Lijie He,Qiang Fu,Junzhe Hu

DOI: https://doi.org/10.3389/fonc.2021.759015

IF: 4.7

2021-11-11

Frontiers in Oncology

Abstract:Immune checkpoint inhibitors (ICIs), Ipilimumab, Nivolumab, Pembrolizumab and Atezolizumab, have been applied in anti-tumor therapy and demonstrated exciting performance compared to conventional treatments. However, the unsatisfactory response rates, high recurrence and adaptive resistance limit their benefits. Metabolic reprogramming appears to be one of the crucial barriers to immunotherapy. The deprivation of required nutrients and altered metabolites not only promote tumor progression but also confer dysfunction on immune cells in the tumor microenvironment (TME). Glycolysis plays a central role in metabolic reprogramming and immunoregulation in the TME, and many therapies targeting glycolysis have been developed, and their combinations with ICIs are in preclinical and clinical trials. Additional attention has been paid to the role of amino acids, lipids, nucleotides and mitochondrial biogenesis in metabolic reprogramming and clinical anti-tumor therapy. This review attempts to describe reprogramming metabolisms within tumor cells and immune cells, from the aspects of glycolysis, amino acid metabolism, lipid metabolism, nucleotide metabolism and mitochondrial biogenesis and their impact on immunity in the TME, as well as the significance of targeting metabolism in anti-tumor therapy, especially in combination with ICIs. In particular, we highlight the expression mechanism of programmed cell death (ligand) 1 [PD-(L)1] in tumor cells and immune cells under reprogramming metabolism, and discuss in detail the potential of targeting key metabolic pathways to break resistance and improve the efficacy of ICIs based on results from current preclinical and clinical trials. Besides, we draw out biomarkers of potential predictive value in ICIs treatment from a metabolic perspective.

oncology
Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment

Yucheng Zheng,Rongwei Xu,Xu Chen,Ye Lu,Jiarong Zheng,Yunfan Lin,Pei Lin,Xinyuan Zhao,Li Cui

DOI: https://doi.org/10.1038/s41419-024-07122-6

2024-10-27

Cell Death and Disease

Abstract:The tumor microenvironment (TME) orchestrates a complex interplay between tumor cells and immune cells, crucially modulating the immune response. This review delves into the pivotal role of metabolic reprogramming in the TME, highlighting how tumor-derived metabolites influence T lymphocyte functionality and the efficacy of cancer immunotherapies. Focusing on the diverse roles of these metabolites, we examine how lactate, lipids, amino acids, and other biochemical signals act not only as metabolic byproducts but as regulatory agents that can suppress or potentiate T cell-mediated immunity. By integrating recent findings, we underscore the dual impact of these metabolites on enhancing tumor progression and inhibiting immune surveillance. Furthermore, we propose innovative therapeutic strategies that target metabolic pathways to restore immune function within the TME. The insights provided in this review pave the way for the development of metabolic interventions aimed at enhancing the success of immunotherapies in oncology, offering new hope for precision medicine in the treatment of cancer.

cell biology
Editorial: Tumor microenvironment and metabolic reprogramming in cancer

Xiaoling Cui,Xinyu Liu,Rongjie Feng,Xiaohan Wang,Yiju Wei,Houjuan Zhu,Asif Raza,Xingyu Zhu,Hao Chen,Wei Chong

DOI: https://doi.org/10.3389/fimmu.2024.1497966

IF: 7.3

2024-10-08

Frontiers in Immunology

Abstract:most significant aspects of the TME is the metabolic reprogramming that occurs in both cancer cells and the surrounding stromal and immune cells [2]. The following editorial synthesizes insights from eleven recent studies that highlight the intricate relationship between the TME, metabolic pathways, and cancer development, offering new avenues for therapeutic intervention. In conclusion, the studies discussed in this editorial provide a comprehensive overview of the dynamic interplay between tumor metabolism and the microenvironment, highlighting the potential of targeting these interactions to improve cancer treatment. As our understanding of these processes deepens, it opens the door to more effective, personalized therapies that not only target the cancer cells but also modulate the TME to enhance immune responses and overcome therapeutic resistance.The future of cancer therapy lies in the integration of metabolic and immunological insights, paving the way for innovative approaches that could transform patient outcomes.

immunology
A continuous cell line derived from a human primary cutaneous melanoma: Morphologic and karyologic properties

S. Nayak,Carol R. Drogemuller,Y. Pilch

DOI: https://doi.org/10.1002/jso.2930150406

1980-12-01

Journal of Surgical Oncology

Abstract:A continuous tissue culture cell line, JD‐MEL, derived from a primary cutaneous human malignant melanoma, is described. The cultured cells retain the characteristic epithelial morphology of the tumor of origin. The malignant nature of the cell line was demonstrated by the lack of contact inhibition, multilayered growth pattern and the ability to produce tumors in athymic BALB/c mice. Chromosome analysis revealed a near tetraploidy. Distinctive marker chromosomes and a female karyotype were present. No recognizable melanin pigment was identified in the cultured cells.
Metabolic Interplay in the Tumor Microenvironment: Implications for Immune Function and Anticancer Response

Reem Youssef,Rohan Maniar,Jaffar Khan,Hector Mesa

DOI: https://doi.org/10.3390/cimb45120609

2023-12-05

Current Issues in Molecular Biology

Abstract:Malignant tumors exhibit rapid growth and high metabolic rates, similar to embryonic stem cells, and depend on aerobic glycolysis, known as the “Warburg effect”. This understanding has enabled the use of radiolabeled glucose analogs in tumor staging and therapeutic response assessment via PET scans. Traditional treatments like chemotherapy and radiotherapy target rapidly dividing cells, causing significant toxicity. Despite immunotherapy’s impact on solid tumor treatment, gaps remain, leading to research on cancer cell evasion of immune response and immune tolerance induction via interactions with the tumor microenvironment (TME). The TME, consisting of immune cells, fibroblasts, vessels, and the extracellular matrix, regulates tumor progression and therapy responses. TME-targeted therapies aim to transform this environment from supporting tumor growth to impeding it and fostering an effective immune response. This review examines the metabolic disparities between immune cells and cancer cells, their impact on immune function and therapeutic targeting, the TME components, and the complex interplay between cancer cells and nontumoral cells. The success of TME-targeted therapies highlights their potential to achieve better cancer control or even a cure.

biochemistry & molecular biology
Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy

Jiaqi Li,Jie Qing Eu,Li Ren Kong,Lingzhi Wang,Yaw Chyn Lim,Boon Cher Goh,Andrea L. A. Wong

DOI: https://doi.org/10.3390/molecules25204831

IF: 4.6

2020-10-20

Molecules

Abstract:Targeting altered tumour metabolism is an emerging therapeutic strategy for cancer treatment. The metabolic reprogramming that accompanies the development of malignancy creates targetable differences between cancer cells and normal cells, which may be exploited for therapy. There is also emerging evidence regarding the role of stromal components, creating an intricate metabolic network consisting of cancer cells, cancer-associated fibroblasts, endothelial cells, immune cells, and cancer stem cells. This metabolic rewiring and crosstalk with the tumour microenvironment play a key role in cell proliferation, metastasis, and the development of treatment resistance. In this review, we will discuss therapeutic opportunities, which arise from dysregulated metabolism and metabolic crosstalk, highlighting strategies that may aid in the precision targeting of altered tumour metabolism with a focus on combinatorial therapeutic strategies.

chemistry, multidisciplinary,biochemistry & molecular biology
Targeting metabolism of breast cancer and its implications in T cell immunotherapy

Jialuo Zou,Cunjun Mai,Zhiqin Lin,Jian Zhou,Guie Lai

DOI: https://doi.org/10.3389/fimmu.2024.1381970

IF: 7.3

2024-04-12

Frontiers in Immunology

Abstract:Breast cancer is a prominent health issue amongst women around the world. Immunotherapies including tumor targeted antibodies, adoptive T cell therapy, vaccines, and immune checkpoint blockers have rejuvenated the clinical management of breast cancer, but the prognosis of patients remains dismal. Metabolic reprogramming and immune escape are two important mechanisms supporting the progression of breast cancer. The deprivation uptake of nutrients (such as glucose, amino acid, and lipid) by breast cancer cells has a significant impact on tumor growth and microenvironment remodeling. In recent years, in-depth researches on the mechanism of metabolic reprogramming and immune escape have been extensively conducted, and targeting metabolic reprogramming has been proposed as a new therapeutic strategy for breast cancer. This article reviews the abnormal metabolism of breast cancer cells and its impact on the anti-tumor activity of T cells, and further explores the possibility of targeting metabolism as a therapeutic strategy for breast cancer.

immunology
Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy

Soumaya Kouidhi,Farhat Ben Ayed,Amel Benammar Elgaaied

DOI: https://doi.org/10.3389/fimmu.2018.00353

IF: 7.3

2018-02-23

Frontiers in Immunology

Abstract:Currently, a marked number of clinical trials on cancer treatment have revealed the success of immunomodulatory therapies based on immune checkpoint inhibitors that activate tumor-specific T cells. However, the therapeutic efficacy of cancer immunotherapies is only restricted to a small fraction of patients. A deeper understanding of key mechanisms generating an immunosuppressive tumor microenvironment (TME) remains a major challenge for more effective antitumor immunity. There is a growing evidence that the TME supports inappropriate metabolic reprogramming that dampens T cell function, and therefore impacts the antitumor immune response and tumor progression. Notably, the immunosuppressive TME is characterized by a lack of crucial carbon sources critical for T cell function and increased inhibitory signals. Here, we summarize the basics of intrinsic and extrinsic metabolic remodeling and metabolic checkpoints underlying the competition between cancer and infiltrating immune cells for nutrients and metabolites. Intriguingly, the upregulation of tumor programmed death-L1 and cytotoxic T lymphocyte-associated antigen 4 alters the metabolic programme of T cells and drives their exhaustion. In this context, targeting both tumor and T cell metabolism can beneficially enhance or temper immunity in an inhospitable microenvironment and markedly improve the success of immunotherapies.

immunology

Incorporation and metabolic conversion of saturated and unsaturated fatty acids in SK-Hep1 human hepatoma cells in culture

Targeting metabolism to enhance immunotherapy within tumor microenvironment

Metabolic Reprogramming of Immune Cells in the Tumor Microenvironment

Metabolic reprogramming in tumor immune microenvironment: Impact on immune cell function and therapeutic implications

Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy

Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy

Targeting lipid metabolism reprogramming of immunocytes in response to the tumor microenvironment stressor: A potential approach for tumor therapy

Metabolic reprograming of MDSCs within tumor microenvironment and targeting for cancer immunotherapy

Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer

Metabolic interventions: A new insight into the cancer immunotherapy

The cancer metabolic reprogramming and immune response

Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy

Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints

Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment

Editorial: Tumor microenvironment and metabolic reprogramming in cancer

A continuous cell line derived from a human primary cutaneous melanoma: Morphologic and karyologic properties

Metabolic Interplay in the Tumor Microenvironment: Implications for Immune Function and Anticancer Response

Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy

Targeting metabolism of breast cancer and its implications in T cell immunotherapy

Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy